A Single-Site, In-Clinic Study Evaluating Short-Term Safety, Tolerability And Pharmacokinetic Of VK5211 In Healthy Elderly Subjects Aged 65 Years And Older.
Phase of Trial: Phase I
Latest Information Update: 10 Nov 2016
At a glance
- Drugs VK 5211 (Primary)
- Indications Hip fracture
- Focus Adverse reactions; Pharmacokinetics
- 10 Nov 2016 Results presented at the 5th Fragility Fracture Network (FFN) Global Congress 2016, according to a Viking Therapeutics media release.
- 01 Sep 2016 Results published in the Media Release
- 01 Sep 2016 Results from this trial will be presented the 5th Fragility Fracture Network (FFN) Global Congress 2016, as reported in a Viking Therapeutics media release.